Choosing well and wisely when deciding on the management of chronic lymphocytic leukemia (CLL) has never been more important. Modern therapeutic platforms based on BTK and BCL2 inhibitors have demonstrated efficacy against higher-risk disease, in the relapsed/refractory setting, and as combination or sequential strategies, and newer chemosparing combinations and non-covalent BTKi are poised to overcome ongoing challenges in treatment-naive and pretreated CLL. How will these developments be used going forward, and is long-lasting disease suppression an achievable goal across patient populations and treatment settings? Find out by joining an expert panel convened to take on the challenges of CLL preceding the 2023 ASH Annual Meeting. PeerView’s expert panelists will share real-world cases to provide guidance on how to implement modern treatment protocols and cover topics such as: choosing between continuous BTKi or fixed-duration first-line regimens; the experience with BTKi/BCL2i combination platforms; and the use of sequential therapy with non-covalent BTKi options in relapsed/refractory CLL. In partnership with the CLL Society, these important topics will be framed by patient perspectives, including commentary from CLL survivors, in order to illustrate the real-world impact of well-chosen, evidencebased treatment on patient outcomes.